This study evaluates the effectiveness of astaxanthin in treating experimental proliferative vitreoretinopathy (PVR) in rats.
Methods
Fifty-six Sprague Dawley rats were divided into 4 groups. PVR was induced using dispase and astaxanthin was administered intravitreally at concentrations of 10 ng/μL and 100 ng/μL. The effects on TGF-ß, VEGF, PDGF, FGF2 and IL-1ß were measured by ELISA and retinal changes were analysed histopathologically and immunohistochemically.
Results
Astaxanthin at 10 ng/μL and 100 ng/μL administered to the treatment groups significantly decreased TGF-β, VEGF, FGF2, IL-1, and PDGF levels compared to the sham group (p < 0.05). At the 100 ng/μL dose, more significant decreases were observed, especially in PDGF and IL-1 levels (p < 0.01). Histopathologic scoring revealed that the treated groups had significantly lower PVR scores than the Sham group, with the highest dose showing the greatest improvement (p < 0.01). Furthermore, treated groups exhibited improved retinal architecture and reduced fibrotic tissue formation. Immunohistochemical staining for VEGF was positive in all groups except Control, with no significant differences in VEGF expression intensity between groups.
Conclusion
Astaxanthin effectively reduces both biochemical and histopathological markers of PVR, highlighting its potential as a novel therapeutic agent for managing this challenging condition in clinical practice.
HiltonGMachemerRMichelsR, et al.The classification of retinal detachment with proliferative vitreoretinopathy. Ophthalmology1983; 90: 121–125. doi:https://doi.org/10.1016/S0161-6420(83)34588-7
ArmstrongDAugustinAJSpenglerR, et al.Detection of vascular endothelial growth factor and tumor necrosis factor alpha in epiretinal membranes of proliferative diabetic retinopathy, proliferative vitreoretinopathy and macular pucker. Ophthalmologica1998; 212: 410–414. doi:https://doi.org/10.1159/000027378
DieudonnéSCLa HeijECDiederenRMH, et al.Balance of vascular endothelial growth factor and pigment epithelial growth factor prior to development of proliferative vitreoretinopathy. Ophthalmic Res2007; 39: 148–154. doi:https://doi.org/10.1159/000103234
9.
LeiHVelezGHovlandP, et al.Growth factors outside the PDGF family drive experimental PVR. Invest Ophthalmol Vis Sci2009; 50: 3394–3403. doi:https://doi.org/10.1167/IOVS.08-3042
10.
DaiYDaiCSunT. Inflammatory mediators of proliferative vitreoretinopathy: hypothesis and review. Int Ophthalmol2020; 40: 1587. doi:https://doi.org/10.1007/S10792-020-01325-4
11.
SadakaAGiuliariGP. Proliferative vitreoretinopathy: current and emerging treatments. Clin Ophthalmol2012; 6: 1325–1333. doi:https://doi.org/10.2147/OPTH.S27896
12.
CharterisDGSethiCSLewisGP, et al.Proliferative vitreoretinopathy-developments in adjunctive treatment and retinal pathology. Eye (Lond)2002; 16: 369–374. doi:https://doi.org/10.1038/SJ.EYE.6700194
13.
NakajimaYInokuchiYShimazawaM, et al.Astaxanthin, a dietary carotenoid, protects retinal cells against oxidative stress in-vitro and in mice in-vivo. J Pharm Pharmacol2008; 60: 1365–1374. doi:https://doi.org/10.1211/JPP/60.10.0013
14.
OhgamiKShiratoriKKotakeS, et al.Effects of astaxanthin on lipopolysaccharide-induced inflammation in vitro and in vivo. Invest Ophthalmol Vis Sci2003; 44: 2694–2701. doi:https://doi.org/10.1167/IOVS.02-0822
15.
SuzukiYOhgamiKShiratoriK, et al.Suppressive effects of astaxanthin against rat endotoxin-induced uveitis by inhibiting the NF-kappaB signaling pathway. Exp Eye Res2006; 82: 275–281. doi:https://doi.org/10.1016/J.EXER.2005.06.023
16.
Izumi-NagaiKNagaiNOhgamiK, et al.Inhibition of choroidal neovascularization with an anti-inflammatory carotenoid astaxanthin. Invest Ophthalmol Vis Sci2008; 49: 1679–1685. doi:https://doi.org/10.1167/IOVS.07-1426
17.
KüçüködükAHelvaciogluFHaberalN, et al.Antiproliferative and anti-apoptotic effect of astaxanthin in an oxygen-induced retinopathy mouse model. Can J Ophthalmol2019; 54: 65–74. doi:https://doi.org/10.1016/J.JCJO.2018.02.017
18.
YinYXuNQinT, et al.Astaxanthin provides antioxidant protection in LPS-induced dendritic cells for inflammatory control. Mar Drugs2021; 19: 2–15. doi:https://doi.org/10.3390/MD19100534
19.
GiannaccareGPellegriniMSenniC, et al.Clinical applications of astaxanthin in the treatment of ocular diseases: emerging insights. Mar Drugs2020; 18: 2–4. doi:https://doi.org/10.3390/MD18050239
20.
SzczesniakAMPorterRFToguriJT, et al.Cannabinoid 2 receptor is a novel anti-inflammatory target in experimental proliferative vitreoretinopathy. Neuropharmacology2017; 113: 627–638. doi:https://doi.org/10.1016/J.NEUROPHARM.2016.08.030
StennKSLinkRMoellmannG, et al.Dispase, a neutral protease from Bacillus polymyxa, is a powerful fibronectinase and type IV collagenase. J Invest Dermatol1989; 93: 287–290. doi:https://doi.org/10.1111/1523-1747.EP12277593
23.
Liposome suppression of proliferative vitreoretinopathy. Rabbit model using antimetabolite encapsulated liposomes - PubMed. Accessed October 3, 2023. https://pubmed.ncbi.nlm.nih.gov/1917392/
24.
SteinhorstUHHatchellDLChenEP, et al.Ocular toxicity of daunomycin: effects of subdivided doses on the rabbit retina after vitreous gas compression. Graefes Arch Clin Exp Ophthalmol1993; 231: 591–594. doi:https://doi.org/10.1007/BF00936524
25.
AsariaRHYKonCHBunceC, et al.Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy : results from a randomized, double-blind, controlled clinical trial. Ophthalmology2001; 108: 1179–1183. doi:https://doi.org/10.1016/S0161-6420(01)00589-9
26.
TaşdemirSZilelioğluOBatmanC, et al.Regmatojen retina dekolmanlarında konvansiyonel dekolman cerrahisi ile vitreoretinal cerrahinin karşılaştırılması. Retina-Vitreus2008; 16: 203–207.
27.
Aclacinomycin A in the treatment of experimental proliferative vitreoretinopathy. Efficacy and toxicity in the rabbit eye - PubMed. Accessed October 3, 2023. https://pubmed.ncbi.nlm.nih.gov/8473115/
28.
FındıkHTumkayaLYılmazA, et al.The protective effects of astaxanthin against cisplatin-induced retinal toxicity. Cutan Ocul Toxicol2019; 38: 59–65. doi:https://doi.org/10.1080/15569527.2018.1518330
29.
YamagishiRAiharaM. Neuroprotective effect of astaxanthin against rat retinal ganglion cell death under various stresses that induce apoptosis and necrosis. Mol Vis2014; 20: 1796. https://pmc.ncbi.nlm.nih.gov/articles/PMC4287717/. Accessed March 23, 2025.
30.
TanoYChandlerDMachemerR. Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide. Am J Ophthalmol1980; 90: 810–816. doi:https://doi.org/10.1016/S0002-9394(14)75196-7
31.
HouHNudlemanEWeinrebRN. Animal models of proliferative vitreoretinopathy and their use in pharmaceutical investigations. Ophthalmic Res2018; 60: 195–204. doi:https://doi.org/10.1159/000488492
32.
Tissue dispersion, cell harvest and fluid suspension culture by the use of bacterial neutral protease - PubMed. Accessed October 3, 2023. https://pubmed.ncbi.nlm.nih.gov/817056/
33.
OzerdemUMach-HofacreBKeefeK, et al.The effect of prinomastat (AG3340), a synthetic inhibitor of matrix metalloproteinases, on posttraumatic proliferative vitreoretinopathy. Ophthalmic Res2001; 33: 20–23. doi:https://doi.org/10.1159/000055636
StennKSLinkRMoellmannG, et al.Dispase, a neutral protease from Bacillus polymyxa, is a powerful fibronectinase and type IV collagenase. J Invest Dermatol1989; 93: 287–290. doi:https://doi.org/10.1111/1523-1747.EP12277593
36.
Cantó SolerMVGalloJEDoddsRA, et al.A mouse model of proliferative vitreoretinopathy induced by dispase. Exp Eye Res2002; 75: 491–504. doi:https://doi.org/10.1006/exer.2002.2031
37.
ShenMChenKLuJ, et al.Protective effect of astaxanthin on liver fibrosis through modulation of TGF-β1 expression and autophagy. Mediators Inflamm2014; 2014: 3–12. doi: https://doi.org/10.1155/2014/954502
38.
ChoiHDKimJHChangMJ, et al.Effects of astaxanthin on oxidative stress in overweight and obese adults. Phytother Res2011; 25: 1813–1818. doi:https://doi.org/10.1002/PTR.3494
39.
SavurFAydemirOİlhanN. The effect of infliximab and octreotide on cytokine levels experimental proliferative vitreoretinopathy. Cutan Ocul Toxicol2020; 39: 61–66. doi:https://doi.org/10.1080/15569527.2019.1701000
40.
EvrenOTurgutBCelikerU, et al.The impact of octreotide in experimental proliferative vitreoretinopathy. Indian J Ophthalmol2013; 61: 109–114. doi:https://doi.org/10.4103/0301-4738.109380
41.
PeymanGASchulmanJA.Intravitreal surgery, vol. 13. USA: Appleton and Lange, 1994, pp. 587–629.
42.
ConnorTBRobertsABSpornMB, et al.Correlation of fibrosis and transforming growth factor-beta type 2 levels in the eye. J Clin Invest1989; 83: 1661–1666. doi:https://doi.org/10.1172/JCI114065
43.
KitaTHataYAritaR, et al.Role of TGF-β in proliferative vitreoretinal diseases and ROCK as a therapeutic target. Proc Natl Acad Sci U S A2008; 105: 17504. doi:https://doi.org/10.1073/PNAS.0804054105
44.
LyuYXuWZhangJ, et al.Protein Kinase A Inhibitor H89 attenuates experimental proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci2020; 61: 5–11. doi:https://doi.org/10.1167/IOVS.61.2.1
45.
YangMKimchiETStaveley-O’carrollKF, et al.Astaxanthin prevents diet-induced nash progression by shaping intrahepatic immunity. Int J Mol Sci2021; 22: 11037. doi:https://doi.org/10.3390/IJMS222011037/S1
46.
TurgutBUyarFUstundagB, et al.The impact of tacrolimus on growth factors in experimental proliferative vitreoretinopathy. Retina2012; 32: 232–241. doi:https://doi.org/10.1097/IAE.0B013E31821E2207
47.
HashimotoHAraiKHayashiS, et al.The effect of astaxanthin on vascular endothelial growth factor (VEGF) levels and peroxidation reactions in the aqueous humor. J Clin Biochem Nutr2016; 59: 10. doi:https://doi.org/10.3164/JCBN.15-137
48.
UslubasIKanliAKasapM, et al.Effect of aflibercept on proliferative vitreoretinopathy: Proteomic analysis in an experimental animal model. Exp Eye Res2021; 203: 3–5. doi:https://doi.org/10.1016/J.EXER.2020.108425
49.
SperanzaLPesceMPatrunoA, et al.Astaxanthin treatment reduced oxidative induced pro-inflammatory cytokines secretion in U937: SHP-1 as a novel biological target. Mar Drugs2012; 10: 890. doi:https://doi.org/10.3390/MD10040890
